What happened with DVA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
DaVita’s core business is U.S. dialysis, mainly through outpatient centers, with home and hospital treatments also available. Patients need recurring treatments, and dialysis and related laboratory services generate most of the company’s revenue. Revenue depends on treatment volume and the payment received for each treatment.
Government health programs provide most U.S. dialysis patient-service revenue, especially Medicare and Medicare Advantage. Commercial insurers pay higher rates on average, and their payments generate nearly all of DaVita’s profit. The business therefore depends heavily on patients retaining commercial coverage and on negotiated insurer rates. When Medicare becomes a patient’s primary payer, payment generally falls to a lower rate.
Medicare pays a fixed bundled amount for each treatment that includes certain drugs and most laboratory services, rather than paying separately for everything used. This limits what DaVita can collect as treatment costs change; quality performance can also reduce payments. Each Medicare-certified dialysis center must have a medical director, so operations depend partly on retaining nephrologists, who also refer patients.
DaVita also operates dialysis centers outside the United States. Its smaller Integrated Kidney Care business manages care for people with kidney disease on behalf of health plans and government programs, earning contract fees or payments tied to care costs and performance.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Fresenius Medical Care competes with DaVita for kidney-failure patients through its dialysis clinics, with both paid under similar reimbursement systems. Its dialysis-care results offer a comparison for how those payment systems affect the business of treating patients.
DaVita buys kidney-disease medicines from Akebia Therapeutics, Inc., so purchase terms and the fixed payments covering dialysis treatment affect what DaVita retains after drug costs. Watch Akebia’s supply terms for Auryxia, used to control phosphorus in dialysis patients, as the extra Medicare payment for phosphate binders is set to expire at the end of 2026.
DaVita pays Rockwell Medical, Inc. for concentrates used in hemodialysis, accounting for 16% of Rockwell’s net product sales in 2025. The purchase agreement’s extension through December 2026 includes another price increase, making contract pricing a concrete item to watch for DaVita’s supply costs.
UnitedHealth Group’s commercial and Medicare Advantage insurance businesses pay for DaVita’s dialysis treatments: those payments are medical costs for UnitedHealth and negotiated reimbursement revenue for DaVita.
Cigna Group’s health insurance business pays DaVita for covered members’ dialysis treatments, linking Cigna’s dialysis medical expenses to the commercial insurance payments that are highly profitable for DaVita.
Outset Medical, Inc. sells hospitals Tablo dialysis equipment and support to run treatments themselves, competing with the hospital dialysis services they buy from DaVita. Watch hospitals’ adoption of that in-house model against DaVita’s hospital inpatient dialysis business, which accounted for approximately 6% of its U.S. dialysis revenue.
Fed Interest Rate Decision
The Fed’s decision sets the economy-wide benchmark for borrowing costs, which can change what DaVita pays on its variable-rate debt and leave less or more cash for operations and investment.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed’s policy rate is above expectations, rates on debt that resets are likely to rise, increasing DaVita’s interest expense and reducing cash available to fund its dialysis operations and development spending.
If it comes in below expectations
If the Fed’s policy rate is below expectations, rates on debt that resets may fall, easing DaVita’s interest expense and leaving more cash available for its dialysis operations and development spending.
DaVita Inc. earningsThis company
DaVita’s U.S. dialysis business earns revenue per treatment, and this report will show whether that revenue and treatment volume are keeping up with staffing and drug costs.
Read U.S. dialysis treatment volume alongside revenue per treatment and patient-care cost per treatment. If treatments hold steady and revenue per treatment grows faster than care costs, payments are still covering staffing and drug pressures; if treatments fall or costs rise faster, DaVita’s dialysis profit is under pressure.
Fresenius Medical Care AG earningsFMS
Fresenius Medical Care and DaVita both run dialysis clinics, so Fresenius Medical Care’s report can show how similar payment systems are affecting treatment activity and costs.
Look at Fresenius Medical Care’s disclosed dialysis activity and whether payment revenue is keeping pace with staffing and supply costs; do not compare headline revenue or earnings per share directly, since the companies’ businesses and reporting bases may differ. Steady activity with payments covering costs suggests similar payment systems can support dialysis care; weaker activity or faster cost growth flags a pressure DaVita may also face, but does not establish DaVita’s own results.
The Cigna Group earningsCI
Cigna pays for dialysis for some DaVita patients, and its report can show whether medical costs are increasing pressure on the insurer to control spending.
Read Cigna’s medical-cost trend and its discussion of healthcare spending. Rising costs could push the insurer to press harder on provider payments, increasing rate pressure on DaVita’s commercially insured dialysis business; contained costs would show less evidence of that pressure. Cigna’s overall medical costs are not DaVita’s dialysis bill and do not reveal DaVita’s specific rates.
Akebia Therapeutics, Inc. earningsAKBA
DaVita uses Akebia’s Auryxia in dialysis care, so Akebia’s report can flag whether changes in the drug’s supply or pricing may squeeze what DaVita keeps from each treatment payment.
Watch what Akebia says about Auryxia demand, supply and pricing. Stable supply with no sign of higher costs would suggest less pressure from phosphate binders included in DaVita’s dialysis payments; supply disruption or price pressure would make those fixed payments harder to stretch across drug costs. Akebia’s sales alone do not show DaVita’s actual purchase price or contract terms.
Rockwell Medical, Inc. earningsRMTI
DaVita buys hemodialysis concentrates from Rockwell Medical, whose report can flag supply or pricing pressure on this dialysis input.
Read Rockwell Medical’s discussion of concentrate sales and supply, and watch for cost or pricing pressure. Stable supply without further cost increases would make this dialysis input easier for DaVita to manage; disruption or higher costs could raise DaVita’s patient-care cost per treatment. Rockwell Medical’s sales mix or results do not directly reveal DaVita’s purchase price.
